Amgen Inc. (AMGN) 股票分析

公司概述

Amgen Inc. operates as a global leader in the discovery, development, manufacturing, and delivery of human therapeutics, with a core portfolio including Enbrel for rheumatoid arthritis and Otezla for plaque psoriasis. The company functions within the Healthcare sector, specifically categorized under Drug Manufacturers - General, positioning it as a critical player in pharmaceutical innovation and patient care delivery. Its substantial scale is evidenced by a market capitalization of $191.69B, annual revenue of $36.75B, and an employee base of 31,500 individuals. These financial dimensions indicate that Amgen maintains a dominant market position within the biotechnology landscape, reflecting its capacity to fund extensive research pipelines and sustain significant operational expenditures.

财务健康

Amgen reported a trailing twelve-month revenue of $36.75B, generating a net income of $7.71B and an EBITDA of $16.62B. The substantial gap between the $36.75B revenue and the $7.71B net income reveals a robust cost structure where operating expenses and taxes consume approximately 79% of top-line growth before reaching the bottom line. The company generated $7.50B in free cash flow, which provides significant financial flexibility to fund capital expenditures, repay debt obligations, or pursue strategic acquisitions without relying on external financing. Profitability is underscored by a gross margin of 70.8%, an operating margin of 30.5%, and a profit margin of 21.0%, all indicating high pricing power and efficient production scales typical of the pharmaceutical industry. Regarding leverage, Amgen holds $9.13B in cash against $55.44B in debt, resulting in a debt-to-equity ratio of 640.27%, which characterizes a highly leveraged balance sheet typical for capital-intensive life sciences firms. Short-term liquidity is assessed via a current ratio of 1.14, suggesting the company possesses just enough current assets to cover its current liabilities, implying a need for careful cash management. Management effectiveness is highlighted by a Return on Equity of 106.1% and a Return on Assets of 7.9%, demonstrating exceptional capital efficiency relative to shareholder equity while maintaining asset productivity.

估值评估

Valuation metrics for Amgen show a trailing P/E ratio of 25.01 compared to a forward P/E of 15.27. This significant disparity implies that the market anticipates a substantial acceleration in earnings growth in the coming years, driving the valuation multiple down from historical levels to reflect expected future profitability. The price-to-book ratio stands at 22.13, indicating that the stock trades at a massive premium over its tangible book value, a common characteristic for companies with intangible assets like patents and proprietary drug formulations. Alternative valuation perspectives include a price-to-sales ratio of 5.22 and an EV/EBITDA of 14.32, which suggest the company is priced aggressively relative to its sales volume but offers reasonable leverage-adjusted earnings multiples. Price action analysis shows a 52-week high of $391.29 and a 52-week low of $261.43, placing the current trading range within the upper band of recent volatility but below the absolute peak. The beta of 0.47 indicates that the stock exhibits significantly lower price volatility relative to the broader market, making it a less sensitive investment to general equity market fluctuations.

Growth & Income

Amgen recorded a revenue growth rate of 8.6% year-over-year alongside an earnings growth rate of 112.1% year-over-year. The fact that earnings growth is vastly outpacing revenue growth implies improved operational leverage, cost efficiencies, or significant price increases on key therapeutic products. As a dividend payer, the company offers a dividend yield of 2.8% with a payout ratio of 66.9%, which suggests the dividend is sustainable given the strong earnings expansion and high return on equity. The elevated payout ratio coupled with robust earnings growth indicates that the company is generating sufficient cash flow to reward shareholders while retaining capital for reinvestment. Overall, Amgen presents a profile characterized by double-digit earnings expansion, a sustainable dividend yield, and a defensive volatility profile within the healthcare sector.